Thyroid Cancer

Women who were diagnosed with thyroid cancer as adolescents or young adults have no difference in pregnancy rates compared with those who have never had thyroid cancer, according to a study published in Thyroid.

The Healio and Endocrine Today editors have compiled the top thyroid news stories from 2022.

Research in 2022 spotlighted several innovative and potentially effective treatment regimens for head and neck cancer.

Overall survival rates for adults diagnosed with anaplastic thyroid carcinoma are similar between those with a history of cancer and those with no previous cancer diagnosis, according to findings published in Thyroid.

A recent study found that patients with type 2 diabetes who used a GLP-1 receptor agonist for more than 1 year had an increased risk for thyroid cancer compared with non-users.

Adults with type 2 diabetes who use a GLP-1 receptor agonist for more than 1 year may have an increased risk for thyroid cancer, according to findings published in Diabetes Care.

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed an update to the ARROW study.

The triplet combination of vemurafenib/cobimetinib/atezolizumab showed improvement in overall survival in patients with BRAF-mutated anaplastic thyroid cancer, according to research presented at American Thyroid Association Annual Meeting.

In this video, Maria E. Cabanillas, MD, an oncologic endocrinologist at The University of Texas MD Anderson Cancer Center, discussed important research on immunotherapy combinations presented at American Thyroid Association Annual Meeting.

In this video, John M. Skaugen, MD, an assistant professor of pathology at University of Pittsburgh discusses his study presented at the American Thyroid Association 2022 annual meeting.